Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.

Frey, Reiner; Unger, Sigrun; van der Mey, Dorina; Becker, Corina; Saleh, Soundos; Wensing, Georg; Mück, Wolfgang

Frey, Reiner; Unger, Sigrun; van der Mey, Dorina; Becker, Corina; Saleh, Soundos; Wensing, Georg; Mück, Wolfgang.

Afiliação

Frey R; Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
Unger S; Global Biostatistics, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
van der Mey D; Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
Becker C; Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
Saleh S; Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
Wensing G; Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
Mück W; Clinical Pharmacology, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.

Pulm Circ ; 6(Suppl 1): S97-S102, 2016 Mar.

Article em En | MEDLINE | ID: mdl-27162633

Palavras-chave

CYP3A4; drug-drug interaction; levonorgestrel-ethinylestradiol; pulmonary hypertension; soluble guanylate cyclase stimulator; steady state

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2016 Tipo de documento: Article